In Apotex, Inc. v. Auspex Pharms., Inc., IPR2021-01507, Paper 9 (P.T.A.B. March 9, 2022), the Patent Trial and Appeal Board exercised its discretion under 35 U.S.C. § 325(d) to deny institution of Apotex's petition for inter partes review.
Snap baut Geschäft mit Computer-Brillen aus msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
STAFFORD, Texas (BUSINESS WIRE) Apr 10, 2021
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the âCompanyâ), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today presented a poster of the final 5 year GP2 Phase IIb clinical trial immune response data at the 2021 AACR Annual Meeting. Immune response is the primary mechanism of action for GP2 and is critical to developing dosing and booster treatment strategies that are designed to achieve and sustain peak immunity, as well as to prevent metastatic breast cancer recurrences.
Figures 1-3 of Poster Presentation CT183 from 2021 AACR Annual Meeting Showing GP2 5 Year Immune Response Data (Graphic: Business Wire)